Approximately 10% of patients with ovarian cancer will develop a recur
rence. Successful treatment of recurring disease has been documented,
and recent developments in chemotherapy are encouraging. In our study,
CA125 Tumour Marker was a useful marker to monitor the course of such
disease, and detected recurring ovarian cancer at a sub-clinical leve
l, leading to earlier diagnosi. This may have implications for outcome
.